Val (EU) xit: do we need an international ISPOR value flower?
J Comp Eff Res
.
2024 Sep;13(9):e240083.
doi: 10.57264/cer-2024-0083.
Epub 2024 Jul 19.
Authors
Sreeram V Ramagopalan
1
2
,
Manuel Gomes
3
,
Isabelle Durand-Zaleski
4
,
Bill Malcolm
5
,
Jose Diaz
5
,
Grace Mitchell
1
,
Jonathan Pearson-Stuttard
1
,
Louis P Garrison Jr
6
Affiliations
1
Lane Clark & Peacock LLP, London, W1U 1DQ, UK.
2
Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK.
3
Department of Applied Health Research, University College London, London, WC1E 6BT, UK.
4
AP-HP Hôtel Dieu, Clinical Research Unit Eco Ile de France, Paris, 75004, France.
5
Global Health Economics & Outcomes Research, Bristol Myers Squibb, Uxbridge, UB8 1DH, UK.
6
The Comparative Health Outcomes, Policy, & Economics (CHOICE) Institute, University of Washington, Seattle, WA 98195, USA.
PMID:
39028108
PMCID:
PMC11363197
DOI:
10.57264/cer-2024-0083
No abstract available
Keywords:
Europe; HTA; ISPOR; value flower.
Publication types
Editorial
MeSH terms
European Union*
Humans